Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences is set to receive an additional patent from the Mexican Patent Office (MPO) for its topical alprostadil-based cream indicated for the treatment of erectile dysfunction (ED), Vitaros.
Subscribe to our email newsletter
The new patent will provide Apricus Bio protection for Vitaros until 2026.
The MPO has issued a ‘notice of allowance for the patent entitled, ‘Topical Stabilized Prostaglandin E Compound Dosage Forms,’ which is expected to be granted within a few months.
Apricus Bio president and CEO Bassam Damaj said Vitaros is now protected in multiple countries by issued patents and they are continuing their efforts to expand the patent portfolio for this important medical innovation.
"We are also engaged in discussions with potential partners in Latin America to license and commercialize Vitaros for ED in certain countries in that region," Damaj said.